| Goodwill and Intangible Assets |
Goodwill and Intangible Assets Intangible Assets As of June 30, 2026, the Company’s intangible assets, net consists of the following: | | | | | | | | | | | | | | | | | | | | | | | | | (in thousands) | Weighted average amortization period | | Gross carrying amount | | Accumulated amortization | | Net carrying amount | | Intangible assets | | | | | | | | | Amortizing intangible assets: | | | | | | | | | Payor contracts | 13 years | | $ | 22,191 | | | $ | (15,115) | | | $ | 7,076 | | | Trade names | 10 years | | 6,650 | | | (4,227) | | | 2,423 | | | Noncompete agreements | 8 years | | 852 | | | (766) | | | 86 | | | Total intangible assets | | | $ | 29,693 | | | $ | (20,108) | | | $ | 9,585 | |
As of December 31, 2025, the Company’s intangible assets, net consists of the following: | | | | | | | | | | | | | | | | | | | | | | | | | (in thousands) | Weighted average amortization period | | Gross carrying amount | | Accumulated amortization | | Net carrying amount | | Intangible assets | | | | | | | | | Amortizing intangible assets: | | | | | | | | | Payor contracts | 13 years | | $ | 22,191 | | | $ | (14,095) | | | $ | 8,096 | | | Trade names | 10 years | | 6,650 | | | (3,900) | | | 2,750 | | | Clinical contracts and noncompete agreements | 8 years | | 926 | | | (757) | | | 169 | | | Total intangible assets | | | $ | 29,767 | | | $ | (18,752) | | | $ | 11,015 | |
The estimated aggregate amortization expense for each of the five succeeding fiscal years as of June 30, 2026 is as follows: | | | | | | | (in thousands) | Amount | | Year ending December 31: | | | 2026 (remaining six months) | $ | 1,409 | | | 2027 | 2,713 | | | 2028 | 2,615 | | | 2029 | 453 | | | 2030 | 453 | | | | | Thereafter | 1,942 | | | Total | $ | 9,585 | |
The aggregate amortization expense during the three months ended June 30, 2026 and 2025 was $716 and $773, respectively. The aggregate amortization expense during the six months ended June 30, 2026 and 2025 was 1,431 and $1,547, respectively. Goodwill The Company evaluates goodwill at the reporting unit level, which, for the Company, is at the level of the reportable segments, specialty pharmacy, patient services, and clinical trials & other. The goodwill allocated to each of the reporting units as of June 30, 2026 and December 31, 2025 is as follows: | | | | | | | | | | | | | (in thousands) | June 30, 2026 | | December 31, 2025 | | Patient services | $ | 2,679 | | | $ | 2,679 | | | Specialty pharmacy | 4,551 | | | 4,551 | | | Clinical trials & other | — | | | — | | | Total goodwill | $ | 7,230 | | | $ | 7,230 | |
|